Phase 3 Readout
IMMP: Phase 3 Topline: AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phas
June 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2026
- Company
- Immutep Limited (IMMP)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phas
- Company
- Immutep Limited (IMMP)
- Indication
- Breast Carcinoma